UNSPSC 51422326: Betamethasone dihydrogen phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJO1F9W10R, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, (11.beta.,16.beta.)-, but more generally known as betamethasone dihydrogen phosphate, which bears US NIH Compound Identifier 107782.

UNSPSC 51422326 Betamethasone dihydrogen phosphate is a Commodity code representing a corticosteroid pharmaceutical product; however, the recent state and local procurement activity tagged under this code shows no direct connection to betamethasone procurement. The single opportunity posted shows a material mismatch between the code's nominal scope and actual buying activity, indicating the code captures little or no relevant recent solicitation volume among state and local agencies.

The most recent opportunity under the code is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive bidding process for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. This procurement—focused on opioid-overdose reversal medication and drug disposal systems—bears no relationship to betamethasone dihydrogen phosphate. The source provides no additional recent opportunities under the code, suggesting limited current state and local procurement activity in this commodity category. Bidders on the Seminole County opportunity must meet E-Verify compliance, drug-free workplace certification, and specified insurance coverage requirements, with the contract structured as an initial two-year term plus a one-year renewal option and a three-month probationary termination period at the county's discretion.